Starting next year, insurance companies, including Highmark, will introduce stricter requirements for covering GLP-1 weight ...

You’ve probably heard about the dramatic weight loss that can happen when you take Ozempic or Wegovy. These medications mimic ...

The Wegovy makers’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in ...

For the first time in a decade, the American Heart Association and American Stroke Association issued new recommendations for ...

Experts from the American Heart Association have released a stroke-prevention guide featuring 'Life's Essential 8' amid a ...

A recent study found significant reductions in opioid overdose and alcohol misuse among people taking GLP-1 drugs like ...

Clinical and other trials for GLP-1 therapies have found an association between these drugs and diabetic retinopathy ...

Novo Nordisk NVO shares have lost 4.5% in the past month compared with the industry’s decline of 1.5%. The company has also ...

Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.

Discover how Novo Nordisk's GLP-1 medication, Rybelsus, reduces major adverse cardiovascular events by 14% in a phase 3 trial, with plans for an expanded label.

In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as ...